From target identification to predictive biomarkers
Nuvisan is a leading provider of omics and biomarker solutions, offering comprehensive support for drug discovery. Whether you need assistance with target identification and validation, mode-of-action studies, compound profiling or the identification of pharmacodynamic and predictive biomarkers for patient stratification, our expert team uses advanced technologies to enhance your project and increase its likelihood of success.
Our cutting-edge functional genomics platform offers versatile tools for drug discovery, including CRISPR/Cas9 genome editing, RNA interference, next-generation sequencing (NGS) and bioinformatics. We provide state-of-the-art NGS and single-cell sequencing technology. Our solutions help identify novel targets and biomarkers and analyse the mode-of-action of compounds with exceptional resolution.
Learn More
Single-cell sequencing is a breakthrough technology that enables whole-genome gene expression profiling of thousands of cells simultaneously. This advancement in transcriptomics greatly enhances the understanding of disease molecular pathophysiology and compound action. Discover our solutions as a certified 10x Genomics single-cell sequencing service provider.
learn more
Our proteomics team leverages advanced techniques to address the complexities of biological systems, uncovering pathways relevant to disease mechanisms and compound action. We tackle the specific scientific challenges of your drug discovery project, delivering quantitative data to identify pharmacodynamic and predictive biomarkers.
learn more
Our biomarker scientists provide tailored approaches to identify and validate pharmacodynamic, target engagement and selection biomarkers. Biomarkers offer valuable insights into the pharmacokinetic/pharmacodynamic relationships of novel compounds and treatment responses. Profiling our tissue biobank identifies relevant patient populations, while analysing biomarkers from clinical trial samples helps ensure seamless translation of preclinical findings into clinical applications.
Learn More
Contact Us
Search